BMY
38
-3
CLX
62
-3
ADI
57
2
PEG
55
2
ABBV
46
4
M
46
6
MSI
54
2
CPB
22
-2
HUM
29
4
AVGO
76
2
SRE
40
3
GME
63
2
EBAY
39
-3
EXR
31
-11
NTRS
39
2
STX
38
4
URBN
75
8
NEE
42
3
K
48
3
WBA
38
-3
BMY
38
-3
CLX
62
-3
ADI
57
2
PEG
55
2
ABBV
46
4
M
46
6
MSI
54
2
CPB
22
-2
HUM
29
4
AVGO
76
2
SRE
40
3
GME
63
2
EBAY
39
-3
EXR
31
-11
NTRS
39
2
STX
38
4
URBN
75
8
NEE
42
3
K
48
3
WBA
38
-3
Financhill
Back

Laird Superfood 10K Form

Sell
35

LSF
Laird Superfood

Last Price:
$7.74
Seasonality Move:
4.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LSF News And Ratings

See the #1 stock for the next 7 days that we like better than LSF

LSF Financial Statistics

Sales & Book Value

Annual Sales: $34.2M
Cash Flow: $305.8K
Price / Cash Flow: 109.71
Annual Sales: $1.27
Price / Book: 6.13

Profitability

EPS (TTM): -0.13000
Net Income (TTM): $-1.3M
Gross Margin: $10.3M
Return on Equity: -9.88%
Return on Assets: -6.96%

Laird Superfood Earnings Forecast

Key Laird Superfood Financial Ratios

  • The Gross Profit Margin over the past 6 years for LSF is 30.13%.
  • The Selling, General & Administrative Expenses for LSF have been equal to 60.75% of Gross Profit Margin.
  • The Research & Development expenses have been 0.64% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of LSF is -29.70% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Laird Superfood Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Food Products
Sector: Consumer Staples
Current Symbol: LSF
CUSIP: 50736T
Website: lairdsuperfood.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.13
Quick Ratio: 1.75

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LSF Technical Analysis vs Fundamental Analysis

Sell
35
Laird Superfood (LSF) is a Sell

Is Laird Superfood a Buy or a Sell?

  • Laird Superfood stock is rated a Sell
    The current Laird Superfood [LSF] share price is $7.79. The Score for LSF is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.